Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.54 - $1.67 $120,767 - $373,485
223,644 New
223,644 $120,000
Q4 2023

Feb 13, 2024

SELL
$1.4 - $2.46 $10,669 - $18,747
-7,621 Reduced 40.56%
11,167 $21,000
Q3 2023

May 14, 2024

BUY
$2.31 - $4.18 $17,604 - $31,855
7,621 Added 68.25%
18,788 $43,000
Q3 2023

Nov 14, 2023

SELL
$2.31 - $4.18 $35,070 - $63,460
-15,182 Reduced 44.69%
18,788 $43,000
Q2 2023

May 14, 2024

SELL
$4.26 - $6.92 $164,414 - $267,077
-38,595 Reduced 53.19%
33,970 $144,000
Q2 2023

Aug 14, 2023

SELL
$4.26 - $6.92 $164,414 - $267,077
-38,595 Reduced 53.19%
33,970 $144,000
Q1 2023

May 14, 2024

BUY
$5.65 - $7.56 $315,168 - $421,711
55,782 Added 332.37%
72,565 $489,000
Q1 2023

May 11, 2023

BUY
$5.65 - $7.56 $315,168 - $421,711
55,782 Added 332.37%
72,565 $489,000
Q4 2022

May 14, 2024

SELL
$5.47 - $7.9 $113,748 - $164,280
-20,795 Reduced 55.34%
16,783 $108,000
Q4 2022

Feb 13, 2023

SELL
$5.47 - $7.9 $113,748 - $164,280
-20,795 Reduced 55.34%
16,783 $108,000
Q3 2022

May 14, 2024

BUY
$7.42 - $11.39 $158,750 - $243,689
21,395 Added 132.21%
37,578 $280,000
Q3 2022

Nov 10, 2022

BUY
$7.42 - $11.39 $158,750 - $243,689
21,395 Added 132.21%
37,578 $0
Q2 2022

May 14, 2024

BUY
$4.96 - $7.83 $24,879 - $39,275
5,016 Added 44.92%
16,183 $108,000
Q2 2022

Aug 15, 2022

SELL
$4.96 - $7.83 $530,516 - $837,488
-106,959 Reduced 86.86%
16,183 $108,000
Q1 2022

May 16, 2022

SELL
$6.33 - $9.53 $51,310 - $77,250
-8,106 Reduced 6.18%
123,142 $823,000
Q4 2021

Feb 14, 2022

BUY
$8.44 - $15.61 $938,443 - $1.74 Million
111,190 Added 554.34%
131,248 $1.24 Million
Q3 2021

Nov 10, 2021

BUY
$5.9 - $12.54 $118,342 - $251,527
20,058 New
20,058 $223,000

Others Institutions Holding XAIR

About Beyond Air, Inc.


  • Ticker XAIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 29,888,000
  • Market Cap $16.1M
  • Description
  • Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment ...
More about XAIR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.